Ausgabe 5/2018
Inhalt (24 Artikel)
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment
Massimo Breccia, Francesca Palandri, Luigiana Luciano, Giulia Benevolo, Massimiliano Bonifacio, Giovanni Caocci, Fausto Castagnetti, Giuseppe A. Palumbo, Alessandra Iurlo, Francesco Landi
Sleep-disordered breathing in patients with sickle cell disease
Vikram M. Raghunathan, Peter L. Whitesell, Seah H. Lim
A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
David Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, Juan Bergua, Rebeca Rodríguez-Veiga, Jordi Esteve, Susana Vives, Josefina Serrano, Belen Vidriales, Olga Salamero, Lourdes Cordón, Amparo Sempere, Ana Jiménez-Ubieto, Julio Prieto-Delgado, Marina Díaz-Beyá, Ana Garrido, Celina Benavente, José Antonio Pérez-Simón, Federico Moscardó, Miguel A. Sanz, Pau Montesinos
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
Alissa Marhäll, Florian Heidel, Thomas Fischer, Lars Rönnstrand
CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study
Guoqing Wei, Yongxian Hu, Chengfei Pu, Jian Yu, Yi Luo, Jimin Shi, Qu Cui, Wenjun Wu, Jinping Wang, Lei Xiao, Zhao Wu, He Huang
Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)
Roberta Di Blasi, Chiara Cattaneo, Russell E. Lewis, Mario Tumbarello, Laura Angelici, Giulia Dragonetti, Alessandro Busca, Benedetta Cambò, Anna Candoni, Monica Cesarini, Simone Cesaro, Mario Delia, Rosa Fanci, Francesca Farina, Mariagrazia Garzia, Antonio Giordano, Bruno Martino, Lorella Melillo, Gianpaolo Nadali, Vincenzo Perriello, Marco Picardi, Angela Maria Quinto, Prassede Salutari, Angelica Spolzino, Adriana Vacca, Calogero Vetro, Michelle Zancanella, Annamaria Nosari, Franco Aversa, Livio Pagano
Leukemia-propagating cells demonstrate distinctive gene expression profiles compared with other cell fractions from patients with de novo Philadelphia chromosome-positive ALL
Hong-Yan Zhao, Yang Song, Xie-Na Cao, Ya-Zhen Qin, Yue-Yun Lai, Hao Jiang, Qian Jiang, Xiao-Jun Huang, Yuan Kong
Prognostic risk models for transplant decision-making in myelofibrosis
Juan-Carlos Hernández-Boluda, Arturo Pereira, Juan-Gonzalo Correa, Alberto Alvarez-Larrán, Francisca Ferrer-Marín, José-María Raya, Joaquín Martínez-López, Patricia Velez, Manuel Pérez-Encinas, Natalia Estrada, Valentín García-Gutiérrez, María-Laura Fox, Angel Payer, Ana Kerguelen, Beatriz Cuevas, María-Antonia Durán, María-José Ramírez, María-Teresa Gómez-Casares, María-Isabel Mata-Vázquez, Elvira Mora, Montse Gómez, Francisco Cervantes
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review
Emanuele Cencini, Alberto Fabbri, Francesco Lauria, Monica Bocchia
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
Guillemette Fouquet, Lionel Karlin, Margaret Macro, Denis Caillot, Murielle Roussel, Bertrand Arnulf, Brigitte Pegourie, Marie Odile Petillon, Claire Mathiot, Cyrille Hulin, Brigitte Kolb, Anne-Marie Stoppa, Sabine Brechiniac, Philippe Rodon, Mamoun Dib, Mourad Tiab, Valentine Richez, Carla Araujo, Marc Wetterwald, Laurent Garderet, Bruno Royer, Aurore Perrot, Lotfi Benboubker, Olivier Decaux, Martine Escoffre-Barbe, Jean Paul Fermand, Philippe Moreau, Hervé Avet-Loiseau, Michel Attal, Thierry Facon, Xavier Leleu
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma
Iris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, Scott Wilhelm, Patrick J. Hayden, Kenneth C. Anderson, Marc S. Raab
Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma
Ying Chen, David R. Lairson, Wenyaw Chan, Xianglin L. Du
PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft
Ping Chen, Xiaofang Wen, Bin Wang, Diyu Hou, Hong Zou, Qin Yuan, Hui Yang, Jieqiong Xie, Huifang Huang
Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Kana Matsuda, Shoko Ono, Marin Ishikawa, Shuichi Miyamoto, Satoshi Abiko, Momoko Tsuda, Keiko Yamamoto, Takahiko Kudo, Yuichi Shimizu, Eiko Hayase, Daigo Hashimoto, Takanori Teshima, Yoshihiro Matsuno, Naoya Sakamoto
Mesenchymal stem cells transplantation in hematological patients with acute graft-versus-host disease: characteristics and risk factors for infectious complications
Igor Stoma, Igor Karpov, Svetlana Krivenko, Igor Iskrov, Natalia Milanovich, Alla Koritko, Anatoly Uss
Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India
Tridip Chatterjee, Amit Chakravarty, Sudipa Chakravarty
Polyneuropathy and myopathy in beta-thalassemia major patients
P. Nemtsas, M. Arnaoutoglou, V. Perifanis, E. Koutsouraki, G. Spanos, N. Arnaoutoglou, P. Chalkia, D. Pantelidou, A. Orologas
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma
Marcel Nijland, Tom van Meerten, Annika Seitz, Gerwin Huls, Robby Kibbelaar, Lydia Visser, Anke van den Berg, Arjan Diepstra
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization
Saki Minoda, Takashi Akasaka, Yusuke Okanoue, Gen Honjo, Miho Nakagawa, Hitoshi Ohno
Infections associated with ruxolitinib: study in the French Pharmacovigilance database
Pinel Sylvine, Sternjacob Thomas, Eftekhari Pirayeh
Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma
Hugo J.A. Adams, Thomas C. Kwee
Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia
Yutaro Suzuki, Junji Koya, Kazutoshi Ebisawa, Hiroyuki Abe, Aya Shinozaki-Ushiku, Fumihiko Nakamura, Mineo Kurokawa
Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein
Lisa Tachiki, Zhao Ming Dong, Nicholas Burwick
Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia
David Martínez-Cuadrón, Blanca Boluda, Pilar Martínez, Juan Bergua, Rebeca Rodríguez-Veiga, Jordi Esteve, Susana Vives, Josefina Serrano, Belen Vidriales, Olga Salamero, Lourdes Cordón, Amparo Sempere, Ana Jiménez-Ubieto, Julio Prieto-Delgado, Marina Díaz-Beyá, Ana Garrido, Celina Benavente, José Antonio Pérez-Simón, Federico Moscardó, Miguel A. Sanz, Pau Montesinos